Abstract:The Library of Integrated Network-Based Cellular Signatures (LINCS) project aims to create a network-based understanding of biology by cataloging changes in gene expression and signal transduction that occur when cells are exposed to a variety of perturbations. It is helpful for understanding cell pathways and facilitating drug discovery. Here, we developed a novel approach to infer cell-specific pathways and identify a compound's effects using gene expression and phosphoproteomics data under treatments with different compounds. Gene expression data were employed to infer potential targets of compounds and create a generic pathway map. Binary linear programming (BLP) was then developed to optimize the generic pathway topology based on the mid-stage signaling response of phosphorylation. To demonstrate effectiveness of this approach, we built a generic pathway map for the MCF7 breast cancer cell line and inferred the cell-specific pathways by BLP. The first group of 11 compounds was utilized to optimize the generic pathways, and then 4 compounds were used to identify effects based on the inferred cell-specific pathways. Cross-validation indicated that the cell-specific pathways reliably predicted a compound's effects. Finally, we applied BLP to re-optimize the cell-specific pathways to predict the effects of 4 compounds (trichostatin A, MS-275, staurosporine, and digoxigenin) according to compound-induced topological alterations. Trichostatin A and MS-275 (both HDAC inhibitors) inhibited the downstream pathway of HDAC1 and caused cell growth arrest via activation of p53 and p21; the effects of digoxigenin were totally opposite. Staurosporine blocked the cell cycle via p53 and p21, but also promoted cell growth via activated HDAC1 and its downstream pathway. Our approach was also applied to the PC3 prostate cancer cell line, and the cross-validation analysis showed very good accuracy in predicting effects of 4 compounds. In summary, our computational model can be used to elucidate potential mechanisms of a compound's efficacy.

Integrated analysis identifies interaction patterns between small molecules and pathways.

Exploring Drug Treatment Patterns Based on the Action of Drug and Multilayer Network Model

Systemic Similarity Analysis of Compatibility Drug-Induced Multiple Pathway Patterns in Vivo

Study of Drug Function Based on Similarity of Pathway Fingerprint

Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity

DPADM: a Novel Algorithm for Detecting Drug-Pathway Associations Based on High-Throughput Transcriptional Response to Compounds.

System Level Characterization of Small Molecule Drugs and Their Affected Long Noncoding RNAs

Exploring Drug Combinations in Genetic Interaction Network

Integrating Genomics and Proteomics Data to Predict Drug Effects Using Binary Linear Programming

A Network-Based Pathway-Expanding Approach for Pathway Analysis

Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination.

Prognostic Pathways Guide Drug Indications in Pan-Cancers

Specific gene module pair-based target identification and drug discovery

Integrated edge information and pathway topology for drug-disease associations

Causal Co-Expression Method with Module Analysis to Screen Drugs with Specific Target.

Analyzing of Molecular Networks for Human Diseases and Drug Discovery

Elucidating polypharmacological mechanisms of polyphenols by gene module profile analysis.

Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer

Drug Repositioning Based on Triangularly Balanced Structure for Tissue-Specific Diseases in Incomplete Interactome

Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer.

Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses